Kiniksa Pharmaceuticals, Ltd. financial data

Symbol
KNSA on Nasdaq
Industry
Pharmaceutical Preparations
Location
Clarendon House, 2 Church Street, Hamilton, Bermuda
State of incorporation
Bermuda
Fiscal year end
December 31
Latest financial report
Q1 2024 - Apr 25, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 458 % -6.04%
Quick Ratio 47.2 % +8.91%
Debt-to-equity 19.3 % +2.55%
Return On Equity 2.05 % -96.5%
Return On Assets 1.72 % -96.6%
Operating Margin -10.1 % -209%

Shares

Label TTM Value / Value Unit Change %
Entity Public Float 510M USD +47.2%
Weighted Average Number of Shares Outstanding, Basic 70.6M shares +1.26%
Weighted Average Number of Shares Outstanding, Diluted 70.6M shares +1.26%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 302M USD +27.7%
Research and Development Expense 87.3M USD +45.8%
Operating Income (Loss) -30.5M USD -239%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -21.6M USD -186%
Income Tax Expense (Benefit) -30.2M USD +82.4%
Net Income (Loss) Attributable to Parent 8.65M USD -95.6%
Earnings Per Share, Basic 0.13 USD/shares -95.4%
Earnings Per Share, Diluted 0.13 USD/shares -95.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 141M USD +75%
Cash, Cash Equivalents, and Short-term Investments 214M USD +13.9%
Accounts Receivable, after Allowance for Credit Loss, Current 16M USD +115%
Inventory, Net 27.3M USD +16.4%
Assets, Current 271M USD +16.9%
Deferred Income Tax Assets, Net 215M USD +16.5%
Property, Plant and Equipment, Net 712K USD -48.9%
Operating Lease, Right-of-Use Asset 12.3M USD +136%
Other Assets, Noncurrent 4.13M USD +77.7%
Assets 520M USD +17.3%
Accounts Payable, Current 5.63M USD +305%
Employee-related Liabilities, Current 7.32M USD +29.6%
Accrued Liabilities, Current 44.7M USD +114%
Contract with Customer, Liability, Current 156K USD -97.6%
Liabilities, Current 64.2M USD +75.5%
Contract with Customer, Liability, Noncurrent 11.8M USD -2.89%
Operating Lease, Liability, Noncurrent 9.86M USD +362%
Other Liabilities, Noncurrent 1.89M USD +0.37%
Liabilities 87.8M USD +66.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax -53K USD -196%
Retained Earnings (Accumulated Deficit) -496M USD +1.72%
Stockholders' Equity Attributable to Parent 432M USD +10.7%
Liabilities and Equity 520M USD +17.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 3.99M USD
Net Cash Provided by (Used in) Financing Activities 3.61M USD +3914%
Net Cash Provided by (Used in) Investing Activities 25.5M USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 141M USD +75%
Deferred Tax Assets, Valuation Allowance 46.3M USD +136%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0 pure
Deferred Tax Assets, Gross 269M USD +30.1%
Operating Lease, Liability 13M USD
Depreciation 974K USD -12.2%
Payments to Acquire Property, Plant, and Equipment 84K USD +250%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 8.54M USD -95.7%
Lessee, Operating Lease, Liability, to be Paid 15.1M USD
Property, Plant and Equipment, Gross 8.65M USD +1.29%
Operating Lease, Liability, Current 2.28M USD -34.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.24M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 2.92M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure
Deferred Income Tax Expense (Benefit) 4.37M USD +305%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2.12M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.95M USD
Deferred Tax Assets, Operating Loss Carryforwards 1.13M USD -72.2%
Current Income Tax Expense (Benefit) 3.05M USD -76.8%
Unrecognized Tax Benefits 1.79M USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 3M USD
Additional Paid in Capital 928M USD +3.72%
Current Federal Tax Expense (Benefit) 122K USD -90.7%
Deferred Tax Assets, Net of Valuation Allowance 219M USD +18.2%
Share-based Payment Arrangement, Expense 28.2M USD +12%